EP
ABUS icon

Eversept Partners’s Arbutus Biopharma ABUS Stock Holding History

Eversept Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-97,495
Closed -$712K – 64
2018
Q2 		$712K Sell
97,495
-20,000
-17% -$119K 0.33% 49
2018
Q1 		$587K Buy
117,495
+10,000
+9% +$53K 0.27% 47
2017
Q4 		$543K Buy
+107,495
New +$630K 0.31% 36

Other funds holding ABUS

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Eversept Partners's ABUS Position: Q3 2018 in Review

Eversept Partners sold out of Arbutus Biopharma (ABUS) in Q3 2018, closing a stake of 97,495 shares — an estimated $712K sold.

Eversept Partners first reported a position in ABUS in Q4 2017 and held it in 3 quarters. The position peaked at $712K in Q2 2018. 88 funds tracked by Wall St. Rank hold ABUS as of Q3 2018.

  • Eversept Partners reported no remaining Arbutus Biopharma position as of Q3 2018 after selling out during the quarter.
  • Eversept Partners sold 97,495 Arbutus Biopharma shares in Q3 2018, an estimated $712K.
  • Eversept Partners first reported a position in Arbutus Biopharma in Q4 2017 and held it in 3 quarters.
  • Eversept Partners's Arbutus Biopharma position peaked at $712K in Q2 2018.
  • 88 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2018.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.